No Data
An Intrinsic Calculation For BeiGene, Ltd. (NASDAQ:BGNE) Suggests It's 47% Undervalued
Key Insights The projected fair value for BeiGene is US$317 based on 2 Stage Free Cash Flow to Equity Current share price of US$167 suggests BeiGene is potentially 47% undervalued Analyst price t
Glenmark Pharma Arm to Market Two Beigene Cancer Drugs in India
Glenmark Specialty, a subsidiary of Glenmark Pharmaceuticals (NSE:GLENMARK, BOM:532296), will market Beigene's (SHA: 688235, HKG:6160) oncology medicines, Tislelizumab and Zanubrutinib, in India, acco
BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why
BeiGene, Ltd. BGNE is a next-gen oncology company focusing on discovering and developing innovative and affordable treatments for cancer patients worldwide.
Clinical research tool book “Everything is Visible” officially published and sold
BEIJING, May 20, 2024/PRNewswire/ -- BeiGene (NASDAQ: BGNE; Hong Kong Stock Exchange: 06160; Shanghai Stock Exchange: 688235), a global oncology treatment innovation company, today announced that “Everything Visible: Ten Scenarios for Visualization Applications in Clinical Research and Development” (hereinafter referred to as “Everything Visible”), which it co-organized with the Drug Information Association (DIA) China Digital Health Community (DHC)), has officially launched. “Everything is Visible” book cover “Everything Visible” is a systematic introduction to how data visualization can be applied to clinical medical research
Top Gap Ups and Downs on Thursday: WMT, TM, MUFG and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
BeiGene (06160) grants share options to subscribe for a total of 12,000 American Depositary Shares under the 2016 Options and Incentive Plan
BeiGene (06160) issued an announcement. On May 10, 2024, the Remuneration Committee of the Board of Directors was based on 201...